30 results about "Tumor-Derived" patented technology

The application discloses a separation-free plasma tumor-derived extracellular vesicle detection method, relates to the technical field of biology, and comprises CD63, HER2, GPC1 or / and EpCAM; probe sequences are shown in SEQ ID NO.1-SEQ ID NO.4; the probe is applied to the extracellular vesicle detection reagent in the separation-free plasma, single EVs imaging analysis, detection of the image of a single EV after direct dilution of plasma, dynamic immune detection, and statistics of the number of specifically combined EVs. The application applies the separation-free extracellular vesicle detection probe to the immune detection reagent, avoids the separation process of plasma EVs, does not need to use fluorescence detection, can characterize the single EVs binding kinetics, and can detect 1 target EVs in 350 background particles.

The application discloses application of tumor-derived acellular extracellular matrix in preparation of a drug for promoting angiogenesis and tissue regeneration. The application proposes a strategy for regulating tissue regeneration based on a tumor-derived acellular extracellular matrix microenvironment, combines the high similarity between a tumor microenvironment and a regeneration microenvironment such as angiogenesis, and constructs a novel angiogenesis-promoting biomaterial, so that high-efficiency regeneration is realized in various tissue defects. In addition, the characteristics of rapid proliferation of tumor tissues break through the production capacity bottleneck of a raw material source of a traditional acellular extracellular matrix, and provide sustainable biological raw materials for large-scale production. The application successfully solves the problem that a specific tissue-derived acellular extracellular matrix is difficult to regenerate in a complex damage microenvironment.

Disclosed herein are DNA amplification methods for quantifying DNA fragments of a target DNA in a sample by size. This can be used, for example, to detect tumor-derived viral DNA in blood sample and distinguish it from larger viral DNA from non-tumor sources. In particular, disclosed herein are methods of detecting, monitoring or treating a human papilloma virus (HPV)-associated malignancy in a subject that involves detecting a presence or absence of at least one circulating tumor-derived HPV DNA in a sample from the subject. Kits for accomplishing the same are also provided.

The invention provides a preparation method of SPF (specific pathogen free) pigskin extracellular matrix (ECM) hydrogel. The preparation method comprises the following steps: S1, collecting SPF pigskin and pretreating; s2, the pretreated SPF pigskin is subjected to degreasing treatment; s3, sterilizing and disinfecting the freeze-dried powder, and then carrying out enzymolysis; s4, adjusting the pH and osmotic pressure of supernate after enzymolysis to obtain a hydrogel product. The source of the hydrogel product does not contain non-biological source materials at all, establishment of a three-dimensional cell culture environment and growth of cultured cells, especially organoids are facilitated, and meanwhile the problems of tumor sources, batch differences, high cost, potential safety hazards and the like of existing hydrogel products such as Matrigel and the like are solved. Experimental results show that the pigskin ECM hydrogel with different concentrations and from different ages can support the growth of intestinal organs, and the number of the organs cultured by the SPF pigskin ECM hydrogel with the concentration of 3 mg / mL is even more than that of Matrigel.

The application relates to the technical field of nanomaterials, in particular to an EpCAM aptamer modified nanomaterial and a preparation method and application thereof, wherein the nanomaterial takes carboxylated mesoporous silica nanoparticles as a carrier, and an EpCAM specific DNA aptamer is covalently coupled to the surface of the nanomaterial; the sequence of the EpCAM specific DNA aptamer is shown as SEQ ID No. 1. The nanomaterial can specifically capture tumor-derived exosomes (EVs) in blood, and can realize sensitive detection of EVs in the 7-day (early stage) and 21-day (late stage) stages of an HT29 colon cancer model and the 7-day stage of an A549 / H460 lung cancer model, thereby providing a minimally invasive liquid biopsy new tool for early diagnosis of colon cancer and lung cancer, and solving the inherent limitation problems of sensitivity and specificity of existing diagnosis means in cancer detection.

Disclosed herein are compositions of antigen-presenting tumor cells (APTCs) and tumor-derived antigen-presenting vesicles (Tumor-APVs) derived from APTCs and methods of their use.

This invention belongs to the field of biomedical technology and provides the application of exosome-derived TRIM59 inhibitors in regulating macrophage M2 polarization and combating oral squamous cell carcinoma. The TRIM59 inhibitor uses exosomes derived from oral squamous cell carcinoma tissue as carriers, with the surface modified with the M2 macrophage-targeting molecule M2pep, internally loaded with TRIM59 inhibitors and KRT6B inhibitors, and loaded with STING pathway agonists. This invention relies on the microenvironment targeting and membrane surface targeting modification of tumor-derived exosomes to precisely deliver TRIM59 inhibitors and KRT6B inhibitors to M2 macrophages and tumor cells. By silencing TRIM59, the resistance of M2 macrophages to the STING pathway is relieved, forming a temporal synergistic effect of first unlocking and then activating with the STING agonist, driving macrophages to M1 polarization.

The invention belongs to the technical field of biological detection, and particularly relates to a synchronous detection sensor for two membrane proteins of tumor-derived small extracellular vesicles based on CRISPR / Cas9. Comprising the following steps: (1) aptamers AptEGFR and AptPD-L1, which are targeted to EGFR (epidermal growth factor receptor) and PD-L1; the magnetic nano particles are modified with an aptamer AptEpCAM (Aptamer EpCAM); (2) a compound of sgRNA1, sgRNA2 and Cas9 protein, wherein the sgRNA1 and the sgRNA2 can be hybridized with nucleic acid sequences at the tail parts of the aptamers AptEGFR and AptPD-L1; the long-stem hairpin probe W1 and the long-stem hairpin probe W2 can be respectively identified by the sgRNA1 and the sgRNA2 and can be cut by the Cas9 protein to release ssDNA Act1 and Act2; (3) hairpin probes H1, H2, H3 and H4; cHA1 is formed by the Act1, the hairpin probe H1 and the hairpin probe H2, and CHA2 is formed by the Act2, the hairpin probe H3 and the hairpin probe H4. The sensor provided by the invention has potential clinical application value in lung cancer screening and auxiliary diagnosis.

Various embodiments of the present invention provide compositions of tumor-infiltrating lymphocytes (TILs) enriched with tumor-reactive cells. The embodiments also provide methods for producing tumor-reactive TILs enriched with tumor-reactive cells, and the use of the provided enriched tumor-reactive TILs for treating cancer in humans or other subjects. According to the embodiments, a tumor-reactive T cell enriched pharmaceutical T lymphocyte infiltration (TIL) composition comprises an oligoclonal population of tumor-infiltrating T cells, including tumor-derived CD4+ and CD8+ T cells, with up to 40 clones constituting 40% of the TCR frequency in the population. Embodiments of the present invention are particularly useful for treating tumors that are resistant or refractory to conventional chemotherapy, or that have become resistant or refractory.

The invention belongs to the technical field of medicines, and particularly relates to a construction method of a peripheral blood circulating tumor DNA and RNA co-construction library and a kit for detecting tumor mutation. The invention provides a peripheral blood circulating tumor DNA and RNA co-construction library and a construction method thereof. By adopting the ctDNA and ctRNA co-established library, more tumor-derived mutations can be detected, mutation types missed by the ctDNA library are found, and mutation characteristic identification of tumor cells of tumor patients is realized more accurately and sensitively.

The invention discloses a pharmaceutical composition containing a tumor-derived acellular extracellular matrix and an application of the pharmaceutical composition. The invention provides a strategy for regulating and controlling tissue regeneration based on a tumor-derived acellular extracellular matrix microenvironment, a novel angiogenesis promoting biological material is constructed by combining the high similarity of a tumor microenvironment and a regeneration microenvironment such as angiogenesis, and high-efficiency regeneration is realized in various tissue defects. In addition, due to the characteristic of rapid proliferation of the tumor tissue, the productivity bottleneck of a traditional acellular extracellular matrix raw material source is broken through, and sustainable biological raw materials are provided for large-scale production. The method successfully solves the problem that a specific tissue-derived acellular extracellular matrix is difficult to regenerate in a complex damaged microenvironment.

The invention relates to a lung nodule benign and malignant diagnosis method based on a proximity linking technology. The method comprises the following steps: 1) extracting and purifying exosome; s1) preparing plasma; s2) preparing an aqueous two-phase system; s3) collecting the exosome; and 2) detecting a protein signal. The method for diagnosing benign and malignant pulmonary nodules based on the proximity link technology is integrally based on a peripheral blood exosome extraction and purification technology, tumor-derived proteins are concentrated and enriched, then protein signals are subjected to exponential amplification by utilizing a trace hydroxylated lysine protein detection technology, and the detection result is obtained. Therefore, the detection sensitivity and accuracy are improved.

The invention relates to a tumor-derived IgG (immunoglobulin G) antibody coupled human recombinant ferritin loaded CpG nano tumor vaccine. The nano tumor vaccine comprises a human recombinant ferritin core-shell structure, a tumor-derived IgG antibody is coupled to the surface of the human recombinant ferritin core-shell structure, and CpG is carried on the core of the human recombinant ferritin core-shell structure. The invention also relates to application of the nano tumor vaccine in treatment of melanoma.

Neuroendocrine tumors (NETs) are a class of highly heterogeneous tumors derived from neuroendocrine cells. Synaptic vesicle 2 (SV2) protein is a novel marker of NETs, and there are three subtypes of SV2A, SV2B and SV2C, wherein the structure of SV2C is more stable than the other two, and the largest cavity ring L4 thereof is the most important binding area with toxins. The present application obtains a nanobody of the extracellular soluble part L4 of SV2 by screening through phage display technology, and the nanobody labeled with a fluorescein, a small molecule of a chemical toxin or a nuclide is used to prepare a probe molecule, and the result can be specifically combined with neuroendocrine tumor cells. The present application provides a nanobody of the extracellular soluble part L4 of SV2, and the nanobody can be applied in the preparation of diagnostic and therapeutic preparations for neuroendocrine tumors.

Provided herein are methods for differentiating from each other, at least in part, using a computer, a tumor-derived nucleic acid variation and a non-tumor (e.g., a potential-undetermined clonal hematopoietic (CHIP))-derived nucleic acid variation in a test sample obtained from a test subject, and a method for differentiating, from each other, a tumor-derived nucleic acid variation and a non-tumor (e.g., a potential-undetermined clonal hematopoietic (CHIP))-derived nucleic acid variation in a test sample obtained from the test subject. Other aspects relate to methods of treating a disease in a subject. Yet other aspects include related systems and computer readable media for differentiating tumor-derived and non-tumor-derived nucleic acid variations from each other.

Provided herein are methods for enriching tumor derived EVs or brain-derived EVs from a biological sample, e.g. a biofluid, using a lectin or glycan-binding fragment thereof and an isolation component (e.g., a solid media). The present disclosure also provides compositions and kits for isolating brain-derived EVs or tumor derived EVs, and compositions comprising an isolated population of brain-derived EVs or tumor derived EVs.

The application discloses tumor-derived exosomes, complement C3 as a marker for kidney cancer metastasis and application thereof, and belongs to the tumor immunity field.The first aspect of the application relates to a kidney cancer metastasis detection kit, comprising: a reagent for detecting complement protein C3, and application of the reagent in preparation of a product for detecting kidney cancer metastasis.The second aspect of the application relates to application of a reagent for inhibiting complement protein C3 in preparation of a medicine for treating kidney cancer.The application provides a new thought for diagnosis and treatment of kidney cancer metastasis, and provides a new research direction for development of a kidney cancer related kit and medicine.

A disease classification method includes determining, using a predictive model, whether cell-free nucleic acid samples are tumor-derived or non-tumor derived based on at least one of the cell-free nucleic acid score or a tumor fraction regression (TFR) score satisfying a respective threshold. The TFR score is determined based on a quantification of an observed tumor-associated aberrant methylation of each of a plurality of cell-free nucleic acid samples using a TFR model. The TFR score includes a fraction of molecules of the plurality of cell-free nucleic acid samples that indicate a tumor. The cell-free nucleic acid score is indicative of the presence of a tumor, and is based on at least one of epigenetic factors or genomic alterations of the cell-free nucleic acid samples.

The invention discloses a healthy individual-derived autologous tumor stem cell line establishment method, which is characterized by comprising the following two stages: a first stage, inducing healthy human-derived somatic cells into hiPSC; in the second stage, the hiPSC is induced to be converted into the tumor stem cells, specifically, firstly, a tumor-derived conditioned culture medium is prepared, then under the synergistic effect of the tumor-derived conditioned culture medium and an induction adjuvant, the hiPSC is induced to be converted into the tumor stem cells, and the healthy individual-derived tumor stem cells are obtained after culture. According to the invention, the somatic cell-derived iPSC of healthy people can be induced into tumor stem cells, and the method can be well applied to cancer prevention, drug screening and health management.

Provided herein is the method for producing TIL through (i) pre-REP amplification step, (ii) co-culture with dendritic cells that present tumor-specific antigen, (iii) co-culture with tumor-derived organoid, (iv) selection of tumor-reactive TIL, and (v) rapid expansion of the tumor-reactive TIL, or combination thereof.The therapeutic and diagnostic materials that result are also disclosed.

Provided herein are methods for distinguishing between tumor- and non-tumor-origin nucleic acid variants in cell-free nucleic acid (cfNA) samples. Particular of these methods include: creating a tumor variant dataset comprising a population of reference tumor-associated gene variants, wherein the tumor variant dataset comprises observation frequency data between reference samples comprising a reference plasma-only sample and a reference leukocyte sample for tumor-associated gene variants in the population of reference tumor-associated gene variants; and determining the ratio of the observation frequency data between the reference samples for tumor-associated gene variants in the population of reference tumor-associated gene variants to generate a relative prevalence dataset. Additional methods and related systems and computer-readable media are also provided.

This invention belongs to the field of pharmaceutical technology, specifically relating to a method for isolating ovarian cancer-related mesenchymal stem cells and their application in anti-tumor treatment. The isolation method includes the following steps: (S1) extracting and isolating mesenchymal stem cells from fresh tumor samples from ovarian cancer patients using the direct tissue block method; (S2) sequentially screening and confirming the mesenchymal stem cells as tumor-derived through cell morphology identification, surface marker analysis, iterative stemness detection, and tumor and / or fibroblast marker exclusion experiments. Experiments have demonstrated that ovarian cancer-related mesenchymal stem cells can be used to evaluate the anti-tumor efficacy of drugs, their anti-invasive ability against tumor matrix support, and / or their anti-globulinization ability against tumor matrix support.

The present invention successfully introduced a new approach to target specific EV subpopulations based on charge-mediated fusion of EVs with CLIP. By adjusting the surface charge of liposomes through the ratio of positively and negatively charged lipids, we identified the optimal ratio for efficient and stable fusion with exosomes. Taking advantage of CLIP's high fusion rate, rapidity, and broad applicability, the present method demonstrated excellent sensitivity and selectivity for tumor-derived EV miRNAs in a lysis-free manner using droplet microfluidics. In particular, the EV-CLIP method enabled digital detection of EGFR L858R and T790M mutations without full sample processing, simplifying the detection process and preventing EV loss.

Disclosed herein are DNA amplification methods for quantifying DNA fragments of a target DNA in a sample by size. This can be used, for example, to detect tumor-derived viral DNA in blood sample and distinguish it from larger viral DNA from non-tumor sources. In particular, disclosed herein are methods of detecting, monitoring or treating a human papilloma virus (HPV)-associated malignancy in a subject that involves detecting a presence or absence of at least one circulating tumor-derived HPV DNA in a sample from the subject. Kits for accomplishing the same are also provided.

Described here is an extracellular vesicle termed pyosomes and methods of preparing them. A method of preparing isolated pyosomes includes providing an ex-vivo tumor cell, treating the tumor cell with a pyroptosis-inducing agent under conditions for the tumor cell to undergo pyroptosis and produce pyosomes, and isolating the pyosomes from the treated tumor cells. The product of the foregoing process is also included. Also described is an immunostimulant composition wherein the pyosomes are loaded with an immunostimulant compound. The immunostimulant composition can be in the form of a pharmaceutical composition such as an implantable pharmaceutical composition. Further described are methods of treating a patient in need of treatment for solid tumors or post-surgical tumor recurrence by administering to the patient the immunostimulant composition.

Provided herein are methods for distinguishing between nucleic acid variants of tumor origin and nucleic acid variants of non-tumor origin in cell-free nucleic acid (cfNA) samples.Certain of these methods include: generating a tumor variant dataset comprising a population of reference tumor-associated genetic variants, wherein the tumor variant dataset comprises the frequency of observation data between reference samples, comprising a reference body fluid (e.g., plasma) sample and a reference non-body fluid (e.g., non-plasma) sample, for tumor-associated genetic variants in the population of reference tumor-associated genetic variants; and determining the ratio of the frequency of observation data between reference samples for tumor-associated genetic variants in the population of reference tumor-associated genetic variants to generate a relative prevalence dataset.Further methods and related systems and computer-readable media are also provided.

This invention provides methods, kits, and systems for isolating extracellular vesicles (EVs) rich in cancer-related miRNAs. It also provides methods, kits, and systems for detecting cancer-related miRNA biomarkers from such EVs. These methods, systems, and kits can be used for the diagnosis, prognosis, and prediction of recurrence risk of specific cancers.

The application discloses a cancer non-invasive early screening method and system based on cfDNA sequencing coverage depth characteristics near TSS. The method realizes non-invasive early screening of cancer by establishing an early screening model of cancer through statistical difference of sequencing data coverage depth mode of tumor-derived cfDNA and cfDNA derived from healthy individuals near TSS through a low-depth whole genome sequencing method. The region of 500bp [‑250bp, 250bp] upstream and downstream of TSS is defined as a central region, and the upstream [‑2000bp,‑1000bp] and downstream [1000bp, 2000bp] of TSS are peripheral regions; the NF value of a gene is the average coverage of the central region divided by the average coverage of the peripheral region. The application adopts a low-depth whole genome sequencing method, greatly reduces the cost, and can detect abnormal changes of fragments earlier than cfDNA mutations in the early stage of cancer, and the method is more sensitive than detecting cfDNA mutation information.

The present disclosure provides methods for distinguishing virion DNA from tumor-derived viral DNA within viral nucleic acid sequences by determining a DNA methylation status of the viral nucleic acid sequence. The methods are used for diagnosing and treating cancer. The method of diagnosing a subject with cancer or treating cancer in a subject comprises identifying a viral nucleic acid sequence in a sample as virion DNA or tumor-derived viral DNA including determining a DNA methylation status of the viral nucleic acid sequence. The methylation of the viral nucleic acid sequence is indicative of tumor-derived viral DNA and the absence of methylation of the viral nucleic acid sequence is indicative of virion DNA.